¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Alcohol Drug Res"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • designer drug
    º¯Á¶¾à¹°
  • fixed drug eruption
    °íÁ¤¾à¹°¹ßÁø, °íÁ¤¾àÁø
  • gateway drug
    Åë·Î¼ö´Ü¾à¹°, ½À°üÇü¼º¾à¹°
  • generic drug name
    ÀϹݾà¸í
  • hallucinogenic drug
    ȯ°¢Á¦
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • inotropic drug
    ¼öÃàÃËÁø¾à
  • mucosal protective drug
    Á¡¸·º¸È£Á¦
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • narcotic drug
    ¸¶¾à
  • new drug application
    ½Å¾àÇã°¡½Åû
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • orphan drug
    Èñ±Í¾à
  • prescription drug
    󹿾à
  • prokinetic drug
    À§Àå¿îµ¿ÃËÁøÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • drug utilization review
    ¾à¹°»ç¿ë°ËÅä
  • drug-induced hemolysis
    ¾àÁ¦À¯¹ß¿ëÇ÷
  • drug-induced hepatitis
    ¾à¹°°£¿°
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • drug-induced purpura
    ¾à¹°À¯¹ßÀÚ»ö¹Ý
  • drug-induced retinopathy
    ¾àÀ¯¹ß¸Á¸·º´Áõ
  • drug-induced rhinitis
    ¾à¹°À¯¹ßÄÚ¿°, ¾à¹°À¯¹ßºñ¿°
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
  • hallucinogenic drug
    (¢¡hallucinogen) ȯ°¢Á¦
  • hematinic drug
    Á¶Ç÷Á¦
  • hematological drug
    Ç÷¾×ÀÛ¿ë¾à
  • inotropic drug
    ¼öÃàÃËÁø¾à
  • mucosal protective drug
    Á¡¸·º¸È£Á¦
  • narcotic drug
    ¸¶¾à
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • application of drug in root canal
    ±Ù°ü÷¾à¹ý(ÐÆÎ·ôäå·Ûö).
  • arsenic drug
    ºñ¼Ò¾à(Ý÷áÈå·).
  • autonomic drug
    ÀÚÀ²½Å°æ°è(ÀÛ¿ë)¾à.
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý.
  • bacterium, drug resistant
    ¾àÁ¦³»¼º¼¼±Õ
  • barbiturate drug
    ¹Ù¸£ºñÅõ¸£»ê¿°¾à.
  • biological drug
    »ý¹°ÇÐÀû Á¦Á¦(?Ì¡?).
  • biological drug
    »ý¹°ÇÐÀû Á¦Á¦(¡­ð²ð¥).
  • bioreductive drug
    »ýüȯ¿ø¼º¾àÁ¦, -¾à¹°
  • bullous drug eruption
    ¼öÆ÷¼º ¾àÁø(¡­å·òÖ)
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • cardiotropic drug
    ½ÉÀåģȭ¼º ¾àÁ¦
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug(=enhancer)
    ÀÎÁö±â´ÉȰ¼ºÁ¦(ìãò±Ñ¦ÒöüÀàõð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
alcoh alcohol, alcoholic, alcoholism
AlcR, alcR alcohol rub
AOB accessory olfactory bulb; alcohol on breath
APH alcohol-positive history; alternative pathway hemolysis; aminoglycoside phosphotransferase; antepart...
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
FAE Fetal alcohol exposed
FAE Fetal alcohol exposure
HAD High Alcohol Drinking
HLADH Horse liver alcohol dehydrogenase
LADH Liver alcohol dehydrogenase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • habit forming drug
    ½À°ü¼º ¾àǰ
    À°Ã¼Àû ¶Ç´Â Á¤½ÅÀûÀ¸·Î ÀÇÁ¸¼ºÀ» °®°Ô ÇÏ´Â ¾à¹°.
  • hydantoinlike drug
    È÷´ÜÅäÀÎ¾ç ¾àÁ¦
  • hydrophilic drug
    Ä£¼ö¼º ¾àÁ¦
  • immunosuppressive drug
    ¸é¿ª ¾ïÁ¦Á¦
    »ýüÀÇ ¸é¿ª ¹ÝÀÀÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦. »ýü ³»¿¡¼­ ¸é¿ª ¹ÝÀÀÀ¸·Î Á¶Á÷ÀÌ Àå¾Ö¸¦ ¹Þ¾Æ º´ÀÌ ÀϾ´Â °æ¿ì°¡ ÀÖ´Ù. ƯÈ÷, Ç׿ø ¹°ÁúÀÌ ÀÚ±âÀÇ Ã¼¼ººÐÀÏ °æ¿ì¿¡´Â ÀÚ°¡ ¸é¿ª ÁúȯÀ̶ó°í ÇÑ´Ù. ÀÚ°¡ ¸é¿ª Áúȯ¿¡¼­´Â ´ë°³ÀÇ °æ¿ì, Á¦ 1¼±ÅÃÁ¦·Î¼­ ºÎ½Å ÇÇÁú È£¸£¸óÀÌ ¾²À̸ç, À̰Ϳ¡ ÀúÇ×À» ³ªÅ¸³»´Â µî ÇѰ谡 ÀÖÀ» °æ¿ì°¡ ÀÖ´Ù. ÀÌ·¯ÇÑ ¶§ ¸é¿ª ¹ÝÀÀÀ¸·Î ÀÎÇÑ º´Å¿¡ ´ëÇÏ¿©, À̸¦ ¾ïÁ¦Çϰí Ä¡·áÇϱâ À§ÇÏ¿© ¸é¿ª ¾ïÁ¦Á¦°¡ »ç¿ëµÈ´Ù. ¶Ç Àå±â ÀÌ½Ä ¶§ °ÅºÎ ¹ÝÀÀÀ» ¾ïÁ¦Çϱâ À§Çؼ­µµ »ç¿ëµÈ´Ù. ¸é¿ª¾ïÁ¦¿¡´Â ±× ¹ÝÀÀ¸¸À» ¾ïÁ¦Çϴ ƯÀÌÇÑ °Í°ú ±×·¸Áö ¾ÊÀº °ÍÀÌ ÀÖÀ¸¸ç, ÀÌ·ÐÀûÀ¸·Î´Â ƯÀÌÇÑ ÂÊÀÇ ÀÛ¿ëÀÌ ¶Ù¾î³ª¾ß ÇϰÚÁö¸¸, ÀÓ»óÀûÀ¸·Î ¾²ÀÌ´Â °ÍÀº °ÅÀÇ ºñƯÀÌÀû ¸é¿ª ¾ïÁ¦Á¦ÀÌ´Ù. ºñƯÀÌÀû ¸é¿ª ¾ïÁ¦Á¦¿¡´Â »çÀÌŬ·ÎÆ÷½ºÆÄ¹Ìµå, ´ÏÆ®·Î°Õ¸¶½ºÅ¸µå µîÀÇ ¾ËųȭÁ¦, 6-¸Þ¸£Ä°ÅäǪ¸°, ¾ÆÀÚÆ¼¿ÀǪ¸°, ½ÃÅä½Å¾Æ¶óºñ³ë½Ãµå µî°ú °°Àº ´ë»ç ±æÇ×Á¦, ¹ÌÅ丶À̽ŠC, ¾ÇƼ³ë¸¶À̽ŠD µîÀÇ Ç×»ý ¹°Áú, ºÎ½Å ÇÇÁú ½ºÅ×·ÎÀ̵åÁ¦, ºó¾ËÄ®·ÎÀ̵åÁ¦, Ç׸²ÇÁ±¸ Ç÷û µîÀÇ Ç×ü µî ¿©·¯ Á¾·ùÀÇ ¾àÁ¦°¡ ÀÖ´Ù. ÀÌµé ¸é¿ª ¾ïÁ¦Á¦´Â Ç׿ø Àڱؿ¡¼­ Ç×ü »ý¼º±îÁö À̸£´Â µ¿¾È¿¡, ¸ÅÅ©·ÎÆÄÁö¿¡ ÀÇÇÑ Ç׿øÀÇ Å½½Ä, ¸²ÇÁ±¸¿¡ ÀÇÇÑ Ç׿ø ÀνÄ, ¼¼Æ÷ ºÐ¿­, T ¼¼Æ÷¿Í B ¼¼Æ÷ÀÇ ºÐ¿­, Ç×ü »ý¼º µî ¸î °¡Áö °úÁ¤À» ÀúÇØ½ÃÅ´À¸·Î½á ¸é¿ª¾ïÁ¦¸¦ ¾ß±â½ÃŲ´Ù. ´ëºÎºÐÀÌ Ç×Á¾¾ç Ȱ¼ºÀ» °¡Áö°í À־, DNA
  • individual drug
    °³°³ÀÎ ¾à¹°
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£ Ç¥Çö
  • lichenoid drug reaction
    ż±¾ç ¾à¹° ¹ÝÀÀ
  • like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • long acting drug
    Áö¼Ó¼º ¾à
  • metabolic drug
    ´ë»ç ¾à¹°
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ¾àǰ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • multiple drug misuse
    ¿©·¯ ¾à¹°ÀÇ ¿À¿ë
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • narcotic drug
    ¸¶¾à
    ¸ð¸£ÇÉ, ÄÚÄ«ÀÎ, ¾ÆÆí µî°ú ±× À¯µµÃ¼·Î¼­ ¹Ì·®À¸·Î °­·ÂÇÑ ÁøÅë ÀÛ¿ë°ú ¸¶Ãë ÀÛ¿ëÀ» Áö´Ï¸ç °è¼Ó »ç¿ëÇÏ¸é ½À°ü¼º°ú Ž´Ð¼ºÀÌ »ý±â°Ô ÇÏ´Â ¹°Áú. »ç¿ëÀ» Áß´ÜÇÏ¸é °Ý·ÄÇÑ ±Ý´Ü Áõ¼¼¸¦ ÀÏÀ¸ÄÑ ¸¶¾àÀ» »ç¿ëÇÏÁö ¾Ê°í´Â Á¤»óÀûÀÎ »ýȰÀ» ÇÒ ¼ö ¾ø°Ô µÇ¸ç, Á¾±¹¿¡ °¡¼­´Â À°Ã¼ÀûÀ¸·Î³ª Á¤½ÅÀûÀ¸·Î ÆóÀÎÀÌ µÇ°Ô ÇÏ´Â ¹°ÁúÀÌ´Ù. ÀÌ·± ¹°ÁúÀÌ ÀÇ·á ¹× ¿¬±¸ ÀÌ¿ÜÀÇ ¸ñÀû¿¡ ³²¿ëµÇ´Â À§ÇèÀ» ¹æÁöÇϱâ À§ÇÏ¿© Á¤ÇÑ ¹ý·ü»ó ¿ë¾î°¡ ¸¶¾àÀÌ´Ù. ¸¶¾àÀº ¨ç ¾Þ¼Ó¿¡¼­ äÃëÇÏ´Â ¾ÆÆí ¾ËÄ®·ÎÀ̵å°è ¸¶¾à
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
fatty alcohol A long chain alcohol, analogous to the fatty acids, of which the fatty alcohol may be viewed as a reduction product; e.g., octadecanol from stearic acid. It is often found esterified in waxes.
Synonym: wax alcohol.
(05 Mar 2000)
foetal alcohol effects A softer diagnosis than foetal alcohol syndrome (FAS). The diagnosis of possible FAE is considered when: 1. The person has some signs of FAS; 2. The person does not meet all of the necessary criteria for FAS; and 3. There is a history of alcohol exposure before birth.
(12 Dec 1998)
foetal alcohol syndrome <syndrome> The most common cause of defective cerebral development in industrialised nations, affecting 1 in 700 live births in the United States. This clinical syndrome results from the direct toxic effects of alcohol on the developing foetus. Growth retardation, mental retardation, small brain and heart valve lesions are common. Infants can be identified by close set eyes, small head, small nasal bridge, reduction in the vermilion border of the upper lip, eye folds and small teeth.
(27 Sep 1997)
4-sulfobenzyl alcohol dehydrogenase <enzyme> Catalyses the formation of 4-sulfobenzaldehyde from 4-sulfobenzyl alcohol; amino acid sequence given in first source
Registry number: EC 1.1.1.-
Synonym: p-sulfobenzyl alcohol dehydrogenase, tsac protein, tsac gene product
(26 Jun 1999)
long-chain-alcohol dehydrogenase <enzyme> Catalyses reversibly the oxidation of a long-chain alcohol in the presence of nad to a long-chain acid anion and NADH
Registry number: EC 1.1.1.192
Synonym: fatty alcohol-nad+ oxidoreductase
(26 Jun 1999)
long-chain-alcohol O-fatty-acyltransferase <enzyme> Catalyses the final step in biosynthesizing storage liquid waxes from long chain fatty acyl CoA and fatty alcohols; forming predominantly c42 wax esters
Registry number: EC 2.3.1.75
Synonym: acyl-coenzyme a-alcohol transacylase, aca transacylase, acyl-CoA-alcohol transacylase, wax-ester synthase
(26 Jun 1999)
abnormalities, drug-induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
(12 Dec 1998)
activity, drug A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa).
(12 Dec 1998)
addictive drug Any drug that creates a certain degree of euphoria and has a strong potential for addiction.
(05 Mar 2000)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
akathisia, drug-induced Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation).
(12 Dec 1998)
antineoplastic drug A drug that stops or slows the maturation and spread of tumour cells (benign or malignant).
(09 Oct 1997)
maintenance drug therapy In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
rational drug design <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it.
(17 Dec 1997)
receptors, drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á